| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2521-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2545-114
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2539-103 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001102 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2015-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ca1c342180228fcc981c3fa59530dfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d0efbbc1ac220b60ec43b86cb6a683d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de37d7dc6b7eb8840fa05d98d551ffb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80fe23e4690f17f0eea921b9787f352b |
| publicationDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017275673-A1 |
| titleOfInvention |
Methods and compositions related to prostate cancer therapeutics |
| abstract |
Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with prostate cancer. Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with castration-resistant prostate cancer wherein such biological molecules and biomarkers comprise androgen-receptor splice variants that can be used to develop effective therapeutic regimens for prostate cancer patients. Disclosed herein are methods of using biological molecules and biomarkers related to androgen-receptor splice variants for assessing therapeutic resistance to drugs such as enzalutamide and abiraterone. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11045564-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1009872-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019155416-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471160-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10398791-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10774387-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2696287-C2 |
| priorityDate |
2014-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |